With sentiment turning against the biotech sector in the public markets, leading European life science venture capital firm Forbion has put together a new fund that could be worth €600m to tap into some of the continent's promising players that are searching for financing for their late-stage projects.
The VC has announced the initial close of €470m ($500m) for its second growth fund to invest in late-stage European life sciences companies
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?